In the present study clinical data and isolates from cases of cryptococcosis recorded during clinical surveys carried out in Italy from 1997 to 2016, were investigated. Molecular typing and antifungal susceptibility testing were performed in order to delineate the epidemiological trend of cryptococcosis in Italy and to define wild-type population for four different antifungal compounds. During the studied period, a total of 302 cases collected from 32 centers of 11 Italian regions were recorded. Analysis of clinical data showed a significant increase of frequency (from 7% to 38%) of cryptococcosis in human immunodeficiency virus (HIV)-negative patients primarily with hematologic malignancies and solid organ transplantations. The prevalence of the molecular types has significantly changed during the study period, showing an increase of VNIII isolates from 11% to 41% in HIV-negative patients, and a decrease of VNIV isolates from 36% to 16%. Antifungal susceptibility testing allowed us to calculate the epidemiological cut-off for flucytosine (1 mg/l), fluconazole (8 mg/l), itraconazole (0.5 mg/l), and voriconazole (0.25 mg/l). Most of the isolates were wild-type strains. Comparison of the MIC distributions according to molecular types showed that VNIV isolates had lower MICs for fluconazole and itraconazole than the VNI and VIII isolates. The current study emphasizes that the epidemiology of cryptococcosis in Italy has significantly changed over the last decades.
Introduction
Cryptococcus neoformans species complex includes encapsulated yeasts responsible for a life-threatening disease usually presenting as meningo-encephalitis and mainly diagnosed in individuals with an impaired immune system. The species complex comprises two varieties and five molecular types: C. neoformans var. grubii (serotype A, molecular types VNI, VNII, VNB) and C. neoformans var. neoformans (serotype D, molecular type VNIV). In addition, intervarietal AD hybrids (molecular type VNIII) are reported. 1 Based on phylogenetic divergence, recently some authors proposed to designate molecular types VNI and VNIV as the separate species: C. neoformans and C. deneoformans, respectively. 2 However, some criticisms against this taxonomic revision were raised by other researchers who, for example, contested the few number of strains used in the analysis (when an MLST database with hundreds of genotypes is available), and the fact that some clades, like VNII and VNB, were not considered species in contrast with others that included only one strain (C. decagattii). 3 Further investigations and discussions are needed to elucidate this important issue. In Italy the epidemiology of cryptococcosis has been studied since 1970. A first retrospective study carried out in Northern Italy reported a high prevalence in human immunodeficiency virus (HIV)-positive (88%) patients and in patients infected with C. neoformans var. neoformans, serotype D strains (71%). 4 Since molecular typing was not yet available, the exact estimation of AD-hybrids was not possible until 1997, when polymerase chain reaction (PCR) fingerprinting allowed to distinguish AD-hybrids from haploid serotype A and D strains. The results showed that a percentage of serotype A and D isolates were actually AD-hybrids and, therefore, that prevalence of hybrids in Italy was higher than previously estimated by serotyping. 5 The first survey on cryptococcosis promoted by Federazione Italiana di Micopatologia Umana ed Animale (FIMUA) was carried out from 1997 to 1999 and involved 29 hospitals in nine Italian regions. 6 The results of the study showed, for the first time, the epidemiological picture of cryptococcosis in Italy. Although the results were not exhaustive at country level, they allowed an estimation of the incidence of cryptococcosis in AIDS patients in the Lombardy region (0.85%) and to prove a different prevalence of the molecular type VNIV Antifungal susceptibility testing for the determination of epidemiological cut-off value (ECV) was also applied to distinguish wild-type from non-wild-type strains since, at present, clinical breakpoints are yet lacking for Cryptococcus. 8, 9 Differently from Candida, Cryptococcus species are nonfermentative yeasts that require oxygen for growth and need constant agitation during incubation. Therefore, antifungal susceptibility testing performed in microdilution plates incubated without shaking is not completely reliable for C. neoformans. 10, 11 An analysis of the variables for standardization of antifungal susceptibility testing of non-fermentative yeasts identified the conditions that make minimal inhibitory concentration (MIC) determination easier, namely yeast nitrogen base (YNB) buffered to pH 7 as growth medium and incubation in agitation. 11 In addition, our previous experience proved that flucytosine MICs obtained using YNB medium at its natural pH 5.4 in shaking incubation correlated with clinical outcome better than those obtained at pH 7.0.
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In the present study, clinical data and isolates collected during surveys carried out in Italy from 1997 to 2016, were analyzed in order to delineate the epidemiological trend of cryptococcosis in Italy, to identify molecular types and to define wild-type population for four different antifungal compounds.
Methods

Isolates and patients
The present analysis includes Italian cases of cryptococcosis recorded during the first prospective survey in the period 1997-1999, 6 those recorded during a second prospective survey from 2010 to 2016, and additional cases recorded retrospectively from 2000 to 2009 based on voluntary notification of some collaborating hospitals. Data concerning demographic, underlying conditions and initial treatment of patients were collected. Isolates, each representative of a single case, were confirmed as C. neoformans by morphology, biochemical tests, and molecular typing.
Molecular typing
Genomic DNA of all isolates was extracted as previously described 13 , and molecular and mating types were determined by multiplex PCRs. 14, 15 Strains H99 (VNI-αA), JEC21 (VNIV-αD), CBS132 (VNIII-αADa), IUM 96-2828 (VNII-aA), JEC20 (VNIV-aD), were used as reference strains.
Antifungal susceptibility testing
MIC was determined by broth microdilution in YNB (Becton Dickinson Italia SpA, Milano, Italy) supplemented with 0.5% glucose, and buffered to pH 7 with MOPS (Sigma Aldrich, St. Louis, MO, USA). Flucytosine was tested in YNB 1% glucose, pH 5.6. Final inoculum was 10 4 CFU/ml.
Antifungal agents tested were fluconazole (Sigma Aldrich), itraconazole (Sigma Aldrich), voriconazole (Sigma Aldrich), and flucytosine (Sigma Aldrich). Final antifungal concentrations ranged from 0.03 to 16 mg/l for itraconazole and voriconazole, and from 0.12 to 64 mg/l for fluconazole and flucytosine. Plates were incubated at 30
• C and shaken at 1400 rpm for 2 min every 30 min. Reading was performed spectrophotometrically at 492 nm after 48 h of incubation. MIC was defined as the lowest drug concentration giving 50% growth inhibition compared to control growth. Candida parapsilosis ATCC 22019 was used as quality control strain.
Statistical analysis
The geometric mean (GM) of MICs and ECV, defined as the MIC that encompassed at least 95% of isolates in the distribution, were calculated. 9, 16 An alternative mathematical method to calculate ECV, using the second derivate of normal distribution, was also applied to confirm the results. (Fig. 1) . Comparison of the distribution of the underlying disease among HIVnegative patients between the periods 1997-99 and 2010-16 showed a statistically significant increase of the cases of cryptococcosis in solid organ transplanted (from 11%, 1/9, to 30%, 12/39) and in patients with hematological malignancies (from 22%, 2/9, to 41%, 16/39) (Fig. 2) . Isolates, most from cerebrospinal fluid and blood (60%, 181/302, and 29%, 87/302, respectively), were identified as C. neoformans var. grubii (C. neoformans) (119/302, namely, 114 molecular type VNI, 4 VNII, 1 VNB), C. neoformans var. neoformans (C. deneoformans) (92/302, 30.5% VNIV) and AD hybrids (C. neoformans x C. deneoformans) (91/302, 30.1% VNIII) ( Table 1) . Comparing the initial period of time (1997-99) with the final one (2010-16), no difference was observed in the prevalence of molecular types VNI and VNIII. On the contrary, the prevalence of molecular type VNIV decreased from 36% (42/118) in 1997-99 to 16% (17/103) in 2010-16 (P < .05) (Fig. 3C) . In addition, when molecular type prevalence was analyzed in HIV-positive and HIV-negative patients we observed a significant increase of infections due to VNIII strains in the latter population (from 11%, 1/9, to 41%, 16/39, p < 0.05) (Fig. 3A, B) . Most of the haploid isolates were mating type αA (118/302), or αD (90/302) except two aD and one aA isolates. The prevalent mating type allelic pattern among the 91 AD-hybrids was αADa (58/91, 64%) followed by aADα (24/91, 26%) (Tab. 1). Regarding MIC distribution, ECVs and percentage of isolates with a MIC less or equal to the ECV are reported in Table 2 . The percentage of isolates with MIC ≤ ECV ranged from 96.9% for voriconazole to 99.7% for itraconazole. Different patterns of susceptibility have been observed in the three most frequently isolated molecular types (Fig. 4) . In particular, VNIV isolates had a pattern of susceptibility to all azoles lower than the other two genotypes. Comparison of MIC distribution of fluconazole and itraconazole between VNIV and VNI isolates and between VNIV and VNIII isolates showed a statistically significant difference (P < .05). All isolates tested with itraconazole were wild-types, except one belonged to molecular type VNI. Four isolates with fluconazole MIC higher than the ECV belonging to molecular type VNIII, and two of them showed also a voriconazole MIC higher than ECV (0.12 mg/l). The other seven non-wild-type isolates for voriconazole included four VNI, one VNIV and further two VNIII isolates. Four isolates showed a high flucytosine MIC (>1 mg/l), namely, three of VNI type and one VNIV. All nonwild-type isolates, except two, were from HIV-positive patients. The two isolates from HIV-negative patients were, one from a kidney transplant recipient (fluconazole MIC = 16 mg/l, and voriconazole MIC = 0.25 mg/l) and the other one from a rheumatologic patient under steroids (voriconazole MIC = 0.25 mg/l). When ECVs were calculated with the alternative method, 17 the values were confirmed except for voriconazole, which was one dilution higher (0.25 mg/l) reducing the number of non-wild-type isolates from nine to four (2 VNI, 1 VNIII, and 1 VNIV).
Discussion
In this study, we analyzed data and isolates collected in Italy in the last 20 years by FIMUA Cryptococcosis Network. By the analysis of underlying conditions, we observed a decline of HIV-associated cases of cryptococcosis in the last period of the survey as a consequence of the introduction of antiretroviral therapy. In the meantime, the number of cases of cryptococcosis in HIV-negative population is increasing, mostly in patients with hematologic malignancies and solid organ transplant recipients. This finding is in agreement with other studies that report cryptococcosis in HIV-negative patients as a rising problem in developed countries. 18, 19 However, the few cases of cryptococcosis recorded in HIV-negative patients during 1997-99 survey could be due to the difficulty of diagnosis in these patients, which has highly improved in the following years. Molecular characterization of 302 clinical isolates showed a similar prevalence among the three most frequent molecular types, 37.7% VNI, 30.5% VNIV and 30.1 VNIII. However, a statistically significant decrease of cases associated with VNIV strains was observed in the last 7 years (2010-2016). This could be explained by the increase of the prevalence of VNIII isolates in HIV-negative patients during the same period, suggesting that AD-hybrids are an emerging cause of cryptococcal infection for this population. Our results showed also that VNIII, together with VNI, molecular types had a higher percentage in non-wild-type strains compared to VNIV. Previous in vivo studies showed that VNIII AD-hybrids included high virulent strains depending on their level of genomic heterozygosity. 20 On the contrary, Desnos-Ollivier et al. 21 , in a clinical survey carried out in France, observed that the infections caused by ADhybrids have a better prognosis than those caused by VNI and VNIV strains. Further studies are required to elucidate the relationship between non-HIV infected patients and VNIII strain infections. Another cause of the decreasing of VNIV prevalence is the reduction of cases in HIVinfected patients. In Italy, the HIV burden was higher in Northern Italy where VNIV prevalence, both in clinical and environmental isolates, 4,6,22 is higher than VNI; therefore, a decreasing of the cases in this region corresponded to a decreasing of overall VNIV prevalence. Comparing the prevalence of molecular types among the Italian clinical isolates with the results reported in other European countries some differences can be observed. VNI prevalence is higher in continental and Northern European countries ranging from 58% in Serbia to 82% in the Netherlands, and is lower in Southern countries ranging from 29% in Spain to = Epidemiological cut-off values calculated as described by Meletiadis et al. 17 50% in Greece. In contrast, VNIII prevalence is high in Portugal (31%), Spain (33%), Italy (37%) and Greece (49%), and lower in the other countries (5-20%). 21, [23] [24] [25] [26] [27] [28] These differences could be explained by the different environmental distribution of C. neoformans molecular types. At present, the few reported environmental VNIII strains were isolated from Greece, Italy, Portugal, and Spain suggesting that these isolates have a higher prevalence in Southern Europe. 22, [29] [30] [31] The ECVs obtained in our set of isolates are identical to fluconazole and voriconazole ECVs reported by Pfaller 8 and identical to those reported by Espinel-Ingroff for itraconazole. 9 On the contrary, our flucytosine ECV (1 mg/L) is lower than flucytosine ECV obtained by Espinel-Ingroff et al.
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(8-16 1 mg/l), but this can be explained by the different media used, YNB pH 5.6 in our study and RPMI-1640 pH 7.0 in Espinel-Ingroff's study. In vitro testing at pH 7.0 was shown to produce higher MICs than at pH 5.6.
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In agreement with other studies conducted worldwide, 8, 24, 26, 28 the majority of isolates (96.9 up to 99.7%)
from Italian patients had a wild-type MIC phenotype for all tested antifungals (fluconazole, itraconazole, voriconazole, and flucytosine). Comparison of susceptibility patterns to azole antifungals in the three most frequent molecular types showed no differences in the MIC distribution of voriconazole and flucytosine. On the contrary, VNIV isolates seems to be more susceptible to fluconazole and itraconazole than VNI and VNIII isolates, suggesting that this molecular type is potentially easier to treat than the two other. VNIV was also the least prevalent among non wild-type groups. In addition, VNIV isolates seems to be less virulent than VNI ones, as confirmed by a previous study where VNI-αA isolates showed a higher mortality than VNIV-αD in a mouse model. 33 Our data also suggest being careful in the choice of ECV calculation method because in some cases a one-dilution discard means to include or exclude several isolates in the non-wild-type group. In the present study, we found two different ECVs for voriconazole using two different methods, and this led to a great difference in the number of non-wild-type isolates of the two cases. The calculation method considering wild-type as the 95% of isolates of the MIC distribution is suitable for unimodal MIC distributions where both or almost both tails are included, whereas the second derivate method is more appropriate if MIC distributions are more braced towards low MICs or for bimodal distributions. 17 In conclusion, the present study emphasizes the emerging of cryptococcosis in HIV-negative Italian patients suggesting the opportunity to screen the serum and/or cerebrospinal fluid for the cryptoccoccal antigen in presence of central nervous system symptoms. The study reveals also a peculiar molecular epidemiology of C. neoformans in Italy showing a high prevalence of VNIII AD-hybrids in agreement with other Southern European countries. Finally, antifungal susceptibility testing confirms that in vitro resistance is an uncommon event, even if different susceptibility patterns were observed comparing the different C. neoformans molecular types.
